GSK3B and cancer: For instance, Pan et al.17reported that AKT/GSK‐3β signalling is activated by CD36 in gastric cancer and regulates downstream β‐catenin to promote the further development of gastric cancer. Therefore, inhibition of AKT/GSK‐3β signalling may be a potential strategy for treating human cancer.